Aerie Pharmaceuticals

Aerie Pharmaceuticals (NASDAQ: AERI) is a publicly traded American biotechnology company. As of January 2016, the company has 3 products in its drug pipeline,[1] including a compound being developed to cure glaucoma.[2][3][4]

References

  1. ↑ "Aerie Pharmaceuticals - Product Portfolio". www.aeriepharma.com.
  2. ↑ Witkowski, Wallace (16 September 2015). "Aerie Pharma Shares Skyrocket On Glaucoma Drug Study Results". Fox Business.
  3. ↑ Beckerman, Josh. "Aerie Pharmaceuticals Shares Rise on Trial Results". Wall Street Journal.
  4. ↑ "Aerie Pharma shares battered as eye drug fails study". Reuters. 23 April 2015. Retrieved 7 January 2016.
This article is issued from Wikipedia - version of the Tuesday, February 23, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.